Skip to main content
Top
Published in: Current Infectious Disease Reports 6/2010

01-11-2010

Vulvovaginal Candidiasis Caused by Non-albicans Candida Species: New Insights

Authors: Melissa A. Kennedy, Jack D. Sobel

Published in: Current Infectious Disease Reports | Issue 6/2010

Login to get access

Abstract

Non-albicans Candida species have increasingly been identified as the cause of vulvovaginitis. In vitro and in vivo data indicate that the various non-albicans Candida species identified in the lower genital tract differ considerably with regard to epidemiology, virulence or vaginal pathogenicity, and antimycotic drug susceptibility. Clinical experience indicates reduced virulence of these organisms in the lower genital tract, and their causal role in a symptomatic patient requires careful case-by-case determination rather than routine administration of antimycotic therapy. Accordingly, vaginal Candida isolates deserve species identification and consideration of pathogenic potential and antifungal susceptibility before therapeutic decisions are made.
Literature
1.
go back to reference • Sobel JD: Vulvovaginal candidosis. Lancet 2007, 369:1961–71. This article provides an extensive review of the epidemiology, diagnosis, and treatment of vaginal Candida infection. CrossRefPubMed • Sobel JD: Vulvovaginal candidosis. Lancet 2007, 369:1961–71. This article provides an extensive review of the epidemiology, diagnosis, and treatment of vaginal Candida infection. CrossRefPubMed
2.
go back to reference Vermitsky JP, Self MJ, Chadwick SG, et al.: Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008, 46: 1501–1503.CrossRefPubMed Vermitsky JP, Self MJ, Chadwick SG, et al.: Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008, 46: 1501–1503.CrossRefPubMed
3.
go back to reference Mohanty S, Xess I, Hasan F, et al.: Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res 2007, 126:216–219.PubMed Mohanty S, Xess I, Hasan F, et al.: Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res 2007, 126:216–219.PubMed
4.
go back to reference Grigoriou O, Baka S, Makrakis E, et al.: Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006, 126:121–125.CrossRefPubMed Grigoriou O, Baka S, Makrakis E, et al.: Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006, 126:121–125.CrossRefPubMed
5.
go back to reference Spinillo A, Capuzzo E, Gulminetti R, et al.: Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol 1997, 176:138–141.CrossRefPubMed Spinillo A, Capuzzo E, Gulminetti R, et al.: Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol 1997, 176:138–141.CrossRefPubMed
6.
go back to reference Fan SR, Liu XP, Li JW: Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006. J Obstet Gynaecol Res 2008, 34:561–566.CrossRefPubMed Fan SR, Liu XP, Li JW: Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006. J Obstet Gynaecol Res 2008, 34:561–566.CrossRefPubMed
7.
go back to reference Ahmad N, Khan AU: Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol 2009, 144:68–71.CrossRefPubMed Ahmad N, Khan AU: Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol 2009, 144:68–71.CrossRefPubMed
8.
go back to reference Hettiarachchi N, Ashbee HR, Wilson JD: Prevalence and management of non-albicans vaginal candidiasis. Sex Trans Infect 2010, 86:99–100.CrossRef Hettiarachchi N, Ashbee HR, Wilson JD: Prevalence and management of non-albicans vaginal candidiasis. Sex Trans Infect 2010, 86:99–100.CrossRef
9.
go back to reference Agatensi L, Franchi F, Mondello F, et al.: Vaginopathic and proteolytic Candida species in outpatients attending a gynaecology clinic. J Clin Pathol 1991, 44:826–830.CrossRefPubMed Agatensi L, Franchi F, Mondello F, et al.: Vaginopathic and proteolytic Candida species in outpatients attending a gynaecology clinic. J Clin Pathol 1991, 44:826–830.CrossRefPubMed
10.
go back to reference • Dennerstein GJ, Ellis DE, Reed CS, Bennett CM: The pathogenicity of non-albicans yeasts in the vagina. J Low Genit Tract Dis 2010 (in press). The authors provide convincing evidence that not all NAC infections require therapy. • Dennerstein GJ, Ellis DE, Reed CS, Bennett CM: The pathogenicity of non-albicans yeasts in the vagina. J Low Genit Tract Dis 2010 (in press). The authors provide convincing evidence that not all NAC infections require therapy.
11.
go back to reference Singh S, Sobel JD, Bhargava P, et al.: Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002, 35:1066–1070.CrossRefPubMed Singh S, Sobel JD, Bhargava P, et al.: Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002, 35:1066–1070.CrossRefPubMed
12.
go back to reference Sobel JD, Chaim W, Nagappan V, Leaman D: Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003, 189:1297–1300.CrossRefPubMed Sobel JD, Chaim W, Nagappan V, Leaman D: Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003, 189:1297–1300.CrossRefPubMed
13.
go back to reference Richter SS, Galask RP, Messer SA, et al.: Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005, 43:2155–2162.CrossRefPubMed Richter SS, Galask RP, Messer SA, et al.: Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005, 43:2155–2162.CrossRefPubMed
14.
go back to reference Sobel JD: Management of infections caused by Candida glabrata. Curr Infect Dis Rep 2000, 2:424–428.CrossRefPubMed Sobel JD: Management of infections caused by Candida glabrata. Curr Infect Dis Rep 2000, 2:424–428.CrossRefPubMed
15.
go back to reference Pfaller MA, Diekema DJ, Gibbs DL, et al.; Global Antifungal Surveillance Group: Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010, 67:162–171.CrossRefPubMed Pfaller MA, Diekema DJ, Gibbs DL, et al.; Global Antifungal Surveillance Group: Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010, 67:162–171.CrossRefPubMed
16.
go back to reference Nyirjesy P, Alexander AB, Weitz MV: Vaginal Candida parapsilosis: pathogen or bystander? Infect Dis Obstet Gynecol 2005, 13:37–41.PubMed Nyirjesy P, Alexander AB, Weitz MV: Vaginal Candida parapsilosis: pathogen or bystander? Infect Dis Obstet Gynecol 2005, 13:37–41.PubMed
Metadata
Title
Vulvovaginal Candidiasis Caused by Non-albicans Candida Species: New Insights
Authors
Melissa A. Kennedy
Jack D. Sobel
Publication date
01-11-2010
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 6/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0137-9

Other articles of this Issue 6/2010

Current Infectious Disease Reports 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.